The United States of America As Represented by the Department of Health

National Institutes of Health, a Component of the US Dept. of Health & Human Services

The United States of America As Represented by the Secretary of

The United States of America As Represented by the Secretary, Department

Stephen D Showalter

Kouji Matsushima

Ettore Appella

Teizo Yoshimura

Edward J Leonard

Berge Hampar

Joost Oppenheim

Joost J Oppenheim

Esther Priel

Donald G Blair

Martin Zweig

An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Neutrophil chemotactic factor cloned cDNA and monoclonal antibodies thereto

An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity of NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Nucleic acids encoding a novel neutrophil chemotactic factor

An isloated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Method of treating inflammation with antibodies to neutrophil

The present invention relates to an isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete coding sequence for NCF.

Antibodies specific for neutrophic chemotactic factor

Neutrophil chemotactic factor

The present invention is directed to the use of pharmaceutical compositions, containing an effective amount of topoisomerase I inhibitor such as camptothecin, useful in blocking both the initiation of infection and replication of retroviruses in host cells, thus reducing and eliminating retroviral production in infected cells. Use of such inhibitors provides as means of reducing or eliminating retroviral infections and their deleterious consequences in infected humans and animals.

Method of treating retroviral infections in mammals

A method and test kit for the serological diagnosis of human infection by herpes sipmlex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) using immunoaffinity purified virus-coded glycoproteins as target antigens. A preferred embodiment of the method employs a variation of the enzyme-linked immunosorbent assay (ELISA) whereby monoclonal antibodies are used to purify target antigens, and test sera are absorbed with virus-infected cell extracts to remove intertypic cross-reacting antibodies.

Enzyme-linked immunosorbent assay (ELISA) for determining anti-bodies

A method for producing monoclonal antibody reagents against novel proteins induced by herpes simplex virus type 1 (HSV-1). The method consists of preparing HSV-1 antigen populations by infecting mammalian cells either with HSV-1 alone or with HSV-1 in the presence of an inhibitor of protein synthesis, allowing virus replication to proceed by reversing the action of said inhibitor, inoculating said antigen mixture in mice to induce the production of antibodies, fusing the spleen cells of said mice with myeloma cells to obtain hybrid cells, and screening said cells by radioimmunoprecipitation-polyacrylamide gel electrophoresis (RIP-PAGE) to identify hybrid cells producing monoclonal antibodies against HSV-1 proteins. The method teaches the production of unique monoclonal antibody reagents directed against novel HSV-1 proteins; including a 132,000 molecular weight (mw) DNA-binding protein, a 175,000 mw immediate-early protein, and a previously unknown 110,000 mw glycoprotein.

Monoclonal antibodies to herpes simplex virus type I polypeptides

A non-transformed cell line is produced by treating BALB/c derived 10E2 cells with 5-bromodeoxyuridine and 5-iodo-2'-deoxyuridine to produce thymidine kinaseless cells which upon multiple cloning show a flat epitheloid appearance indicative of their non-transforming potential. These cells are used to determine the tumorigenic transforming potential of any gene by introducing the gene into the cells of the non-transformed cell line along with the Herpes simplex virus thymidine kinase gene which serves as a vehicle for cotransfection. The transformation of the cells is indicative of tumorigenic potential.

Growing community of inventors

Frederick, MD, United States of America

Stephen D Showalter